Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Caribou Biosciences, Inc.

NASDAQ: CRBU · Life Sciences · 3 alerts · CIK 1619856

Share price
$0.3528Close, Nov 16
Market cap
$38.1M
Shares outstanding
108.04MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Caribou Biosciences, Inc. filings on SEC EDGAR ↗

4:11 PM ET 10-Q
Financial Results

Caribou Biosciences Q3 2026 Results: Net Loss of $26.6M, Loss Narrows

Caribou Biosciences reported a net loss of $76.0 million for the nine months ended September 30, 2026, compared to $121.6 million in the prior year period. Total assets decreased to $123.0 million from $175.4 million at year-end 2025, while the company raised $22.8 million in net proceeds through an at-the-market (ATM) offering during the first nine months of 2026.

Key figure
Net loss $26.6M
4:11 PM ET 8-K
Financial Results

Caribou Biosciences Financial Results

Caribou Biosciences reported Q3 2026 financial results, including a GAAP net loss of $26.6 million on revenue of $1.6 million. The company also highlighted its October 2026 decision to discontinue clinical trials for vispa-cel and CB-011 and reduce its workforce while exploring strategic alternatives such as a merger or acquisition.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.